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ABSTRACT  1 
 2 
Herein we explore a new generation of smart living implants combining not only active 3 
therapeutics but also stem cells, as a novel strategy to regenerate stabilized cartilage and 4 
avoid prosthesis, by achieving regeneration of its subchondral bone foundation, 5 
requirement which is failing today in the clinic. 6 
 7 
Clinical articular cartilage repair: current techniques, opportunities and 8 
drawbacks 9 
The growing aging population suffering from articular knee damage boosts the market 10 
of cartilage regeneration. The cost of cartilage regeneration techniques will restrain the 11 
market in coming years. Emerging technologies such as regenerative nanomedicine is a 12 
growing focus in this market. Smart implants, combing active molecules, scaffolds and 13 
cells are expected to grow at high rates due to a demonstrated higher efficiency over 14 
other cell based therapies. Furthermore, there are about 5.4 million potential patients 15 
who will require joint and cartilage regeneration procedures by 2019 in U.S. alone, a 16 
significant factor driving the overall market of cartilage regeneration. The rationale to 17 
develop a new approach on articular cartilage repair departs from the poor outcome of 18 
focal chondral lesions that are left untreated. Those may progress to debilitating joint 19 
pain, dysfunction and degenerative arthritis, and the development of an early treatment 20 
that controls pain and maintains articular function is a challenging aim. It has been 21 
hypothesized that structural repair of articular cartilage may lead to the desired clinical 22 
outcome, and this belief has fostered new technologies to obtain the best quality hyaline 23 
articular cartilage repair in the focal chondral lesions. 24 
Current clinical treatments include non-transplantation techniques (marrow stimulation 25 
techniques like microfractures are considered the current standard), osteochondral 26 
autograph transfer (such as mosaicoplasty) and cell therapy (autologous chondrocyte 27 
implantation –ACI-), but meta-analysis of randomized controlled trials have not found 28 
differences among these techniques to improve function and pain at intermediate-term 29 
follow-up [1]. Seeding of autologous chondrocytes in a collagen membrane led to the 30 
development of the matrix-applied characterized autologous cultured chondrocytes 31 
implantation (MACI) [2], proving that MACI was superior to microfracture treatment 32 
for symptomatic cartilage defects of the knee, but this technique showed two associated 33 
risks, graft hypertrophy and delamination, and there are insufficient intermediate or 34 
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long-term results to ascertain its real value. The combination of structural membranes, 1 
pluripotent autologous cells and chondroinductive growth factors can be considered the 2 
holy grail of cartilage focal lesions repair. However, it should be stressed that structural 3 
repair is not sufficient: pain and function improvement, and a true functional repair of 4 
the cartilage are considered the main clinically relevant endpoints, at the end of well-5 
designed clinical trials. 6 
 7 
Nanoreservoirs technology for osteochondral regenerative medicine 8 
Nanostructured materials have been widely used in soft tissue engineering as 9 
scaffolding materials (to support cell adhesion, proliferation and differentiation), and as 10 
nanofillers (within scaffolds) acting as depots, for spatio-temporal controlled release of 11 
bioactive molecules. Nanostructured scaffolds are designed to resemble the 3D native 12 
extracellular matrix (ECM) of the regenerated tissue, offering adequate porosity for cell 13 
infiltration and high surface per volume ratio for protein adsorption, and allowing 14 
tunable cell-surface interactions [3]. Nanomedicine allows the emergence of entirely 15 
new classes of active devices intended for targeted intracellular delivery for improved 16 
efficacies and reduced associated toxicities. In cell therapy, nanoparticles internalized 17 
within transplanted cells can also be used as cargos of adjuvant drugs, avoiding the need 18 
of systemic drug administration [4]. As building material, the nanoparticle itself can act 19 
as a tissue-regeneration inductor as in the case of nano-hydroxyapatite, a bone-like 20 
material, which promotes bone regeneration, and has been widely used as nanofiller 21 
within scaffolds in the treatment of osteochondral lesions [5]. We reported the use of 22 
nanostructured capsules incorporating growth factors for bone regeneration by using 23 
stem cells in vivo [6]. Nanoencapsulation of differentiation-inducing molecules within 24 
nanoparticles has also been proven as an efficient and persistent chondrogenic strategy, 25 
preventing an uncontrolled release [7]. In our group, a unique nanotechnology strategy 26 
is used to entrap, protect, and stabilize therapeutic agents into polymer coatings: 27 
nanoreservoirs, covering nanofibres of implantable nanofibrous membranes for bone 28 
and cartilage regeneration [8] (Figure 1). Upon contact with cells, therapeutic agents 29 
become available through enzymatic degradation of the nanoreservoirs. As cells grow, 30 
divide, and infiltrate deeper into the porous membrane, they trigger slow and 31 
progressive release of therapeutic agents that, in turn, stimulate further cell proliferation. 32 
The nanoreservoirs technology enables to reduce the quantities of required therapeutic 33 
agent (compared to soaked membranes for instance) thereby reducing costs.  34 
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 1 
Smart implant combining triple 3D technology and double compartment for 2 
articular cartilage repair  3 
There are some evidences that intra-articular administration of growth factors and 4 
biologics can act on pathologic metabolic changes, but intra-articular injection of cells 5 
does not effectively repopulate the damaged areas. Current cartilage repair techniques 6 
lead to the formation of low quality fibrocartilage instead of hyaline cartilage and often 7 
result in subchondral bone abnormalities. Recently, researches have been focusing their 8 
efforts on the development of bilayered implants, to mimic the natural layers present in 9 
the osteochondral unit [9]. Mesenchymal stem cells (MSCs) from adult bone marrow 10 
provide an exciting and promising stem cell population for the repair of bone in skeletal 11 
diseases. We reported a new generation of nanofibrous implant functionalized with 12 
BMP (Bone morphogenetic proteins) growth factors nanoreservoirs and equipped with 13 
human MSC microtissues (MTs: Cells spheroids) for regenerative nanomedicine [10]. 14 
We reported as well an innovative approach improving cartilage repair, by regenerating 15 
a robust subchondral bone, supporting articular cartilage [11, 12]. This novel strategy 16 
consists in a double compartmented and hybrid implant filled with well-organized 3D 17 
stem cells as spheroids.  It combines three-dimensional structures: stem cells 18 
microtissue, nanofibrous membrane and hydrogel (Figure 2). This triple-3D implant is 19 
able to mimic the physiological environment of the osteochondral unit. Thus, compared 20 
to the treatments on the market today, it offers a double therapeutic action: Instead of 21 
targeting only the cartilage layer, our advanced technology is also engineered to restore 22 
a more stable subchondral bone, and proposes a cell-controlled release of the contained 23 
BMP, which is expected to enhance the treatment efficiency . All these features will 24 
improve the prognostic for the patients by restoring a full articular function.  25 
 26 
Future outlook 27 
Osteochondral regenerative nanomedicine provides a new perspective to face clinical 28 
challenges thanks to the direct interaction at the cellular and molecular level of the 29 
disease and the complete understanding of the interface between biomolecules and 30 
biomaterials. For robust and durable articular cartilage regeneration, it is necessary to 31 
repair this tissue on a solid subchondral bone basis. We report here an innovative 32 
therapeutic medical device based on two designed compartments mimicking the natural 33 
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cues of the osteochondral unit which improves subchondral bone regeneration and 1 
cartilage stabilisation. We see our technology as an adaptable and easy-to-apply 2 
technological platform for various regenerative medicine applications (skin, 3 
vasculature…). By functionalizing the structural scaffold with nanoreservoirs of 4 
adequate therapeutic agents (angiogenic growth factors, anti-cancer drugs, anti-5 
inflammatory molecules, genes…), seeding it with the appropriate cells and shaping it 6 
to the right composite structure, it can be engineered for the treatment of several 7 
pathologies. Our technology can also include other vectors such as nanoparticles, 8 
cyclodextrins used as tools to protect and solubilise drugs as a second level of action in 9 
the nanoreservoirs. Our nanoreservoirs technology can be used by the industry in 10 
biopharmaceutical research to design new combination devices with their own drugs 11 
and/or cell lines. 12 
Although some efforts have to be dedicated to solve the challenges of these 13 
nanotechnologies including industrial scale-up, methods standardization, long-term 14 
validation of the medical outcome, safety and efficacy evaluation compared to the 15 
current clinical practice, we foresee many other future application avenues for our 16 
platform technology in regenerative medicine and eventually in personalized medicine. 17 
 18 
 19 
 20 
ACKNOWLEDGMENTS 21 
 22 
 23 
REFERENCES 24 
 25 
1 Mundi, R., et al. (2015) Cartilage Restoration of the Knee: A Systematic Review and 26 
Meta-Analysis of Level 1 Studies. Am J Sports Med  Jul 2. pii: 0363546515589167, 27 
Published online before print July 2, 2015, doi: 10.1177/0363546515589167 28 
 29 
2 Saris, D., et al. (2014) Matrix-Applied Characterized Autologous Cultured 30 
Chondrocytes Versus Microfracture: Two-Year Follow-up of a Prospective 31 
Randomized Trial. SUMMIT study group. Am J Sports Med  42(6), 1384-1394 32 
 33 
5 
 
3 Shi, J., et al. (2010) Nanotechnology in drug delivery and tissue engineering: From 1 
discovery to applications. Nano Lett 10, 3223-3230 2 
 3 
4 Stephan, M.T., et al. (2010) Therapeutic cell engineering with surface-conjugated 4 
synthetic nanoparticles. Nat Med 16(9), 1035-1041 5 
 6 
5 Kon, E., et al. (2011) Novel nano-composite multilayered biomaterial for 7 
osteochondral regeneration a pilot clinical trial. Am J Sports Med 39, 1180-1190 8 
 9 
6  Mendoza-Palomares,  C., et al. (2010) Active multilayered capsules for in vivo bone 10 
formation. Proc Natl Acad Sci USA 107, 3406-3411 11 
 12 
7 Shi, D., et al. (2016) Photo-cross-linked scaffold with kartogenin-encapsulated 13 
nanoparticles for cartilage regeneration. ACS Nano 26, 1292-1299 14 
 15 
8 Mendoza-Palomares,  C., et al. (2012) Smart hybrid materials equipped by 16 
nanoreservoirs of therapeutics. ACS Nano 6, 483-490 17 
 18 
9 Nooeaid, P., et al. (2012) Osteochondral tissue engineering: scaffolds, stem cells and 19 
applications. J Cell Mol Med 16(10), 2247-2270 20 
 21 
10 Schiavi, J., et al. (2015) Active implant combining human stem cell microtissues and 22 
growth factors for bone-regenerative nanomedicine. Nanomedicine (Lond) 10(5), 753-23 
763 24 
 25 
11 Keller, L., et al. (2015) Double Compartmented and Hybrid Implant Outfitted with 26 
Well-Organized 3D Stem Cells for Osteochondral Regenerative Nanomedicine.  27 
Nanomedicine 10, 2833-2845   28 
 29 
12 Keller, L., et al. (2015) Bi-layered Nano Active Implant with Hybrid Stem Cell 30 
Microtissues for Tuned Cartilage Hypertrophy. J Stem Cell Res & Ther 1(1), 1-9 31 
 32 
 33 
 34 
6 
 
FIGURES 1 
 2 
Figure 1. Nanoreservoirs technology for osteochondral regenerative nanomedicine. 3 
For efficient articular cartilage repair, both the subchondral bone lesion and the cartilage 4 
should be targeted in the treatment. Our strategy depicted here consists in: (i) using a 5 
nanofibrous membrane as structural scaffold mimicking the extracellular matrix to 6 
cover  the subchondral bone lesion (small defects), (ii) membrane fibres  previously 7 
coated with nanoreservoirs containing an osteoinductive agent (BMP) to induce 8 
mineralisation, (iii) and stem cells that can differentiate into both bone (osteoblasts) and 9 
cartilage (chondrocytes) cells. 10 
 11 
Figure 2. Smart implant combining triple 3D technology and double compartment 12 
for articular cartilage repair. 13 
Our hybrid living implant mimics the biological and structural cues of the native 14 
osteochondral unit, leading to both subchondral bone and cartilage repair. The triple 3D 15 
environment design is featured by: (i) hMSCs (from bone marrow) as well-organized 16 
microtissues (MTs), (ii) nanofibrous membrane (collagen or polycaprolactone) 17 
functionalised with nanoreservoirs of BMPs and (iii) alginate/hyaluronic acid hydrogel. 18 
The innovative strategy is based on the combination of this triple 3D environment 19 
organized in a multi-compartmented well-defined structure:  20 
1st compartment: mineralization capacity of hMSC MTs seeded on nanofibrous 21 
membrane; 2nd compartment: chondrogenic capacity of hMSC MTs in alginate/HA 22 
hydrogel; Compartments combination: hMSCs in a triple3D environment for the 23 
osteoarticular unit regeneration. It generates the natural gradient of mineralization in the 24 
physiological osteochondral unit, leading to create the natural ‘glue’ between articular 25 
cartilage and subchondral bone. 26 
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